leslie ballas MD, Presenter: Nothing to Disclose

James Yoon BA, Abstract Co-Author: Nothing to Disclose

Bhushan Desai MBBS, MS, Abstract Co-Author: Nothing to Disclose

Hossein Jadvar MD, PhD, Abstract Co-Author: Nothing to Disclose

To associate NaF PET findings for first bone metastases with PSA values and kinetics in patients with biochemical recurrence in the post-prostatectomy setting.

All NaF PET scans that were performed at USC between 2010 and 2104 were queried to find patients who had undergone radical prostatectomy. We excluded patients who had known metastatic disease at the time of NaF PET to obtain a cohort of patients for whom NaF PET was being used to determine first osseous metastases. The electronic medical records of the patients were then reviewed to extract information on PSA at the time of NaF PET, PSA kinetics, pathologic features of the prostatectomy specimen, as well as other radiologic studies performed to validate the NaF PET findings.

56 patients met our inclusion criteria; of which, 11 (19.6%) had positive NaF PET scans. The average PSA for patients with a positive NaF PET was 6.25 ng/mL (range 0.04– 30.38 ng/mL). There were 14 patients who had imaging studies with PSA values below 0.2ng/mL; 3 of those patients (21%) had positive scans.. The average PSA velocity of patients with positive NaF PET was 0.34 ng/ml/mo (range 0.02 to 2.25 ng/ml/mo), the average PSA doubling-time amongst the patients with positive scans was 9.92 months (range 1.22 – 36.32 months). Of those with positive NaF PET scans, 4 had other imaging modalities that confirmed the existence of bone abnormalities and all 11 were treated for progression of disease based on the findings of the NaF PET scans.

NAF PET detected first osseous metastatic disease in 19.6% of patients with PSA relapse in this population of patients. The test was able to detect early metastatic disease in 3 of 14 patients with PSA values ≤ 0.2ng/mL.

NaF PET has the ability to detect early prostate cancer bone metastases in the post-prostatectomy setting. (This work was done with grant support from Dr. Jadvar's NIH/NCI Grant R01-CA111613).

ballas, l, Yoon, J, Desai, B, Jadvar, H, PSA Sensitivity of 18F-NaF PET for Detection of First Bone Metastases in Biochemical Recurrence of Prostate Cancer after Prostatectomy.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14016155.html